• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cryo-Cell International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    10/12/23 4:30:34 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $CCEL alert in real time by email
    8-K
    false000086269200008626922023-10-102023-10-10

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 10, 2023

     

     

    CRYO-CELL INTERNATIONAL, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40767

    22-3023093

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    700 Brooker Creek Blvd.

     

    Oldsmar, Florida

     

    34677

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 813 749-2100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.01 par value

     

    CCEL

     

    NYSE American LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On October 10, 2023, the Company held its Annual Meeting of Stockholders. At the Annual Meeting, stockholders considered the election of four directors, the ratification of the Company's independent registered accountants and the approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers

     

    The final result of the stockholder vote was certified on October 10, 2023 and is as follows:

     

    1. To consider the election of four individuals to the Company's Board of Directors.

     

    David Portnoy

    For 3,100,610

    Withhold 408,114

     

    Harold Berger

    For 3,119,399

    Withhold 389,325

     

    Mark Portnoy

    For 3,100,159

    Withhold 408,565

     

    Daniel Mizrahi

    For 3,174,329

    Withhold 334,395

     

    2. The ratification of appointment of WIPFLI LLC as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2023.

     

    For Against Abstain

    6,328,614 159,161 4,717

     

    3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.

     

    For Against Abstain

    3,038,636 365,541 104,547

     

     

    4. Authorization to vote the proxies upon other business properly coming before the Meeting or any adjournments or postponements thereof.

     

    For Against Abstain

    3,056,073 409,735 42,916

     

     

    .

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Cryo-Cell International, Inc.

     

     

     

     

    Date:

    October 12, 2023

    By:

    /s/ David Portnoy

     

     

     

    David Portnoy, Chairman and Co-CEO

     


    Get the next $CCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CCEL
    SEC Filings

    View All

    SEC Form 10-Q filed by Cryo-Cell International Inc.

    10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

    4/14/26 5:00:23 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

    3/12/26 5:00:27 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-K filed by Cryo-Cell International Inc.

    10-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

    2/27/26 5:01:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman, Co-CEO Portnoy David

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    1/9/26 5:00:15 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Co-CEO Portnoy Mark L.

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    1/9/26 5:00:06 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 4 filed by Chief Information Officer Mikulinsky Oleg

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    1/9/26 5:00:10 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million in processing and storage fee revenue, $36,000 in product revenue and approximately $1,400 in public banking revenue compared to $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately

    4/14/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cryo-Cell Receives NYSE American Continued Listing Notice

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30,

    3/12/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo

    2/27/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Co-CEO Portnoy David bought $76,486 worth of shares (17,175 units at $4.45), increasing direct ownership by 2% to 827,344 units (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    9/18/25 4:53:49 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Chairman, Co-CEO Portnoy David bought $189,986 worth of shares (42,900 units at $4.43), increasing direct ownership by 0.89% to 811,920 units (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    9/10/25 5:22:01 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Chairman, Co-CEO Portnoy David bought $176,198 worth of shares (39,179 units at $4.50) (SEC Form 4)

    4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

    8/27/25 5:23:37 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Cryo-Cell International Announces Changes To Its Board of Directors

    MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NASDAQ:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company's Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, M.D., who have resigned in their capacity as Directors. Mr. Gaines has chosen to retire while Dr. Wheeler has resigned for health reasons. The Board of Directors voted unanimously in favor of adding Mr. Mark Portnoy and Mr. Daniel Mizrahi as members of the Board. Mr. Portnoy is a Co-CEO of the Company and previously served as a member of the Board of Directors from 2011-2020. Mr. Miz

    9/20/21 6:05:23 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Financials

    Live finance-specific insights

    View All

    Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024. Net (Loss) Income The Company repo

    2/27/26 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cryo-Cell International, Inc. Provides Dividend Update

    Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company", "Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the Company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. This decision reflects lower-than-expected profitability. Cryo-Cell may or may not reinstate a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities. For more information, please visit www.cryo-cell.com or contact Investor Relations at [email protected]. Abou

    8/14/25 8:30:00 AM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend

    Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

    5/8/25 5:00:00 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    $CCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

    SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

    2/14/23 4:14:29 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

    SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

    2/14/22 12:44:18 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care